tbuckley/cabot-search huggingface dataset:
SAT0434 Validation of A Proposed Ultrasonographic Grading Scale for Severity of Primary Knee Osteoarthritis
Authors: M.A. Mortada, M.A. E.-H. Al-Toukhy, N. Ezz Eldein, A. Zeid
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Conventional radiography (CR) is the standard imaging modality in the assessment of knee osteoarthritis (KOA), but Ultrasonography (US) is recognised as a useful imaging modality for the detection of synovitis and osteophytes [1]. <h3>Objectives</h3> to validate a proposed ultrasonographic grading scale for severity of primary knee osteoarthritis. <h3>Methods</h3> The study included 160 knee primary osteoarthritis (KOA) patients with diagnosed according to the clinical or the radiological criteria for of the American College of Rheumatology (ACR) and 20 patients with knee pain but not fulfill ACR criteria for KOA. All patients were subjected to clinical assessment (Western Ontario and McMaster Universities (WOMAC) Index of Osteoarthritis and global visual analogue scale VAS) and radiological assessment in the form of x ray grading according to Kellgren and Lawrence (KL) grading scale (0-4),2 and ultrasonographic assessment of medial femoral osteophytes according to a scale (0-4) that was proposed by the first author as follow: grade 0: No osteophytes; regular ends of both femoral condyle without any projections, grade 1: minor osteophyte; just a small projection from the femoral condyle, grade 2A: Small osteophytes; a projection from the femoral condyle that appears to have a downward part in joint space zone, grade 2B: Large osteophyte appears to be separated from femoral condyle and descending downwards in joint space zone, grade 3: Large osteophyte appears to be separated from femoral condyle and descending downwards in joint space zone with small horizontal extension parallel to femoral bone, grade 4: Mainly horizontal osteophyte parallel to femoral bone. <h3>Results</h3> The proposed Ultrasound grading scale had high sensitivity and specificity in detecting the different grades of KOA compared with KL grading scale (a total sensitivity is 94.6% and a total specificity is 93.3%). Intra and inter-reader reliability of ultrasound was excellent (kappa &gt;0.93 and &gt;0.85 respectively). The proposed US grading scale was highly significantly correlated with age, disease duration and body mass index. While there was non-significant correlation between the proposed US grading scale and VAS and WOMAC subscales and total scale. <h3>Conclusions</h3> Ultrasound can reliably detect the severity of knee osteoarthritis. Good agreement was found between the proposed US grading scale and KL grading scale. The proposed US grading scale is simple and reliable. <h3>References</h3> Abraham AM, et al. BMC Musculoskelet Disord. 2011;14:70. Kellgren JH, Lawrence JS. Oxford: Blackwell Scientific; 1963. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1703
Psychoanalysis and Medicine: A Study of the Wish to Fall Ill.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0397 Increased Bone Mass and Bone Strength by Sclerostin Antibody (Scl-Ab) is Maintained by a RANKL Inhibitor in OVX Rats with Established Osteopenia
Authors: M. Ominsky, X. Li, K. Warmington, Q.-T. Niu, F. Asuncion, D. Dwyer, M. Grisanti, C.-Y. Han, P. Kostenuik, M. Stolina, H. Ke
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Some Scl-Ab-induced BMD gains gradually reversed after treatment discontinuation in rats. <h3>Objectives</h3> To examine if follow-up treatment with a RANKL inhibitor, OPG-Fc, would maintain Scl-Ab-induced bone mass gains in OVX rats. <h3>Methods</h3> Six-month-old OVX rats (2 months post-OVX) were treated with Scl-Ab (Scl-Ab VI, 25 mg/kg, SC, 1x/wk) for 6 wks and then transitioned to vehicle (Veh) or OPG-Fc (10 mg/kg, SC, 2x/wk) for another 6 or 20 wks (n=12-14/group). Veh-treated Sham and OVX control rats were euthanized at wks 0, 6, 12, and 26, and a group of Scl-Ab-treated OVX rats were euthanized at wk 6 (n=10-12/group). <h3>Results</h3> In vivo DXA analysis showed that after 6 wks, Scl-Ab-treated OVX rats increased lumbar spine and femur-tibia BMD to levels significantly above OVX and Sham controls. These treatment-related increases were maintained by transition to OPG-Fc, and gradually reversed by transition to Veh (Fig.). Histomorphometry revealed significant increases in vertebral trabecular bone volume (BV/TV) and tibial cortical thickness (Ct.Th) after 6 wks of Scl-Ab treatment. While transition to OPG-Fc maintained BV/TV and Ct.Th at the peak levels achieved with Scl-Ab, transition to Veh led to gradual declines in these parameters to levels that remained above OVX controls at wk 26. Significant increases in trabecular, endocortical, and periosteal bone formation rates and significant decreases in trabecular and endocortical eroded surfaces were also associated with Scl-Ab treatment (6 wks). Transition to OPG-Fc led to reductions in each of these bone resorption and formation parameters, however transition to Veh reversed these changes. At wk 26, maximum load of lumbar vertebral bodies was significantly greater in the OPG-Fc vs Veh transitioned group. <h3>Conclusions</h3> After discontinuing Scl-Ab treatment, transitioning to the RANKL inhibitor OPG-Fc effectively inhibited bone resorption and maintained Scl-Ab-induced bone mass and bone strength gains. <h3>Disclosure of Interest</h3> M. Ominsky Shareholder of: Amgen Inc., Employee of: Amgen Inc., X. Li Shareholder of: Amgen Inc., Employee of: Amgen Inc., K. Warmington Shareholder of: Amgen Inc., Employee of: Amgen Inc., Q.-T. Niu Shareholder of: Amgen Inc., Employee of: Amgen Inc., F. Asuncion Shareholder of: Amgen Inc., Employee of: Amgen Inc., D. Dwyer Shareholder of: Amgen Inc., Employee of: Amgen Inc., M. Grisanti Shareholder of: Amgen Inc., Employee of: Amgen Inc., C.-Y. Han Shareholder of: Amgen Inc., Employee of: Amgen Inc., P. Kostenuik Shareholder of: Amgen Inc., Employee of: Amgen Inc., M. Stolina Shareholder of: Amgen Inc., Employee of: Amgen Inc., H. Ke Shareholder of: Amgen Inc., Employee of: Amgen Inc.
AB0910 Ultrasonographic Finginds in Chronic Haemophilic Arthropathy on A Population of Children: Table 1.
Authors: N. Ange, M. Lamyae, R. Hanan, R. Maria, K. Mohammed, K. Mohammed, A. Fadoua, H.H. Najia
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> We aimed to describe the ultrasonographic findings in chronic haemophilic arthropathy. <h3>Methods</h3> Twenty-six children (mean age 11.3±3.8 years [4-18], all male, were included in this study; twenty-three of them (88.5%) had severe haemophilia. All patients have at least one joint affected by chronic haemophilic arthropathy. Sixty-one joints were sonographicaly examined with a high-frequency probe (7-14Mhz) in Doppler and B modes. Following ultrasonographic parameters were analysed: synovitis, doppler activity, joint effusion, bone erosion, osteophytes and foreign bodies. <h3>Results</h3> Chronic haemophilic arthropathy affected knees elbows and ankles in respectively 49, 31.1 and 19.6%.Chronic haemophilic arthropathy affected more than one joint in 87%. The table summarizes ultrasonographic findings in joints examined. <h3>Conclusions</h3> Ultrasonography seems to be be an interesting tool to show as well patterns of disease flare than joints status. This simple and practical examination should be intagred in practice to monitoring children suffering from chronic hemophilic arthropathy especially in developing countries. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4561
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months
Authors: A. Sobrero, A. Grothey, S. Siena, A. Falcone, M. Ychou, Y. Humblet, O. Bouche, L. Mineur, C. Barone, A. Adenis, J. Tabernero, T. Yoshino, H. Lenz, R.M. Goldberg, L. Xu, A. Wagner, E. Van Cutsem
Journal: Annals of Oncology (2015)
P13.14 * PROPHYLACTIC USE OF SHIUNKO IN THE PREVENTION OF RADIATION-INDUCED SCALP DERMATITIS: A PRELIMINARY REPORT
Authors: A. Hayashi
Journal: Neuro-Oncology (2014)

INTRODUCTION: Radiation-induced scalp dermatitis, a complication of radiotherapy for brain tumors, may impair the quality-of-life (QOL) of patients. Steroid ointments have been considered as the only effective treatment, but the author had reported that shiunko,a sort of oriental ointments, could relief well the symptoms of radiation-induced scalp dermatitis [Kampo Med 62(2):142-146, 2011]. In this preliminary study, In this preliminary study, the author hypothesized that the prophylactic use of shiunko could prevent or alleviate radiation-induced scalp dermatitis. MATERIALS AND METHOD: Ten patients (male 4 and female 6, ranges between 21 to 79 years-old, mean 60.3 years-old,) with malignant brain tumors were involved in this study. Radiation dose ranges between 45 to 60 Gy, mean 54.7 Gy). Shiunko was applied to the whole radiated field consecutively during the entire period of radiotherapy. The efficacies were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. RESULTS: Favorable therapeutic effects were observed in all patients. The scalp conditions were maintained well until the end of radiotherapy. The radiation dermatitis of all patients was estimated as Grade 1. But loss of hair was not avoided. DISCUSSION: Shiunko, which is covered by the Japanese health-insurance system for treating burns, is composed of only five natural remedies: lithospermi radix, angelicae radix, sesame oil, beeswax, and lard. Despite its simplicity, it has several unique activities, such as anti-bacterial activity, detoxification, anti-histamine activity, and moist wound healing. Furthermore, recent studies demonstrated vascular endothelial growth factor (VEGF) production and apoptosis induction, which promote wound healing. These preliminary results showed that shiunko is expected to be an effective ointment in preventing radiation-induced scalp dermatitis.
SP0130 How to treat juvenile idiopathic arthritis and other paediatric rheumatic diseases
Authors: N. Wulffraat
Journal: Annals of the Rheumatic Diseases (2013)

Diagnosis and management of pediatric rheumatic diseases has changed markedly in the past decade. Paediatric rheumatic diseases differ significant from their adult counterpart. For instance the ILAR classification of Juvenile Idiopathic Arthritis has 7 subtypes. Only the RF positive JIA subtype, accounting for just 5-7% of JIA cases, closely resembles adult RA. The most prevalent subtypes are poly articular RF negative JIA (28%) and oligoarticular JIA (30—56%). Stills disease is very rare in adults whereas it accounts for 10-20% paediatric cases. Treatment algorithms are subtype specific. In contrast to RA, JIA is often self limiting, especially the oligoarticular subtype. Treatment aims at early recognition and adequate suppression of inflammation followed by efforts of tapering the medication used. For instance in about 50% of children with JIA, MTX can be stopped successfully. Biomarkers of a specific clinical course under MTX treatment are however lacking. Criteria for inactive disease on/off medication have been defined, and recently detailed recommendations for treatment including biologics were published by a combined US-European task force. For JIA biologics such as etanercept, adalimumab and abatacept are registered for JIA, whereas registration of tociluzimab and cankinumab will soon be registered for use in systemic onset JIA (SJIA). Anakinra is used off label for S-JIA. Indications for treatment and evaluation of efficacy will be discussed. Key issue in treatment algorithms is identification of risk factors and lack of response to previous therapies. Similar to early arthritis treatment strategies in RA, high risk JIA (poly JIA, SJIA) should be recognised and treated early. There appears to be a window of opportunity created by early aggressive treatment inducing remission followed by tapering of medication. Experience with the use of biologics in JIA is relatively recent and we should be vigilant of possible unknown long term side effects. To this purpose a European pharmacovigilance initiative called PharmaChild was recently launched. <h3>Disclosure of Interest</h3> None Declared
Abstract 2724: Intravesical treatment with Vesicular Stomatitis virus decreases the size of bladder tumors without adversely affecting the health and well-being of immune-competent mice
Authors: Lisa A. Skinner, Kevin Zhang, William Jia, Paul Rennie, Alan So
Journal: Cancer Research (2011)

Abstract Recent studies have shown that wild-type Vesicular Stomatitis virus (VSV) and the Δ51M recombinant IFN-inducing mutant of wild-type VSV (AV3) have powerful oncolytic activity against bladder cancer cells in an immune-compromised bladder cancer model. The objective of the current study was to determine the safety and efficacy of the wild-type VSV and AV3 when intravesically administered to an immune-competent bladder cancer model. Using an established orthotopic bladder cancer model, 100 µL of 108 pfu mL−1 wild-type VSV, AV3, or UV-inactivated wild-type VSV (UVI) was instilled into the urinary bladders of female C3H mice. Half of the mice had normal, healthy bladders and were instilled with the oncolytic virus on day 0, 2, and 4. The remaining mice were given non-muscle invasive bladder tumors through the transurethral instillation of luciferase expressing MBT-2 mouse bladder carcinoma cells. On day 5 after initial tumor inoculation, tumor-bearing mice were imaged for bioluminescence and tumor size was quantified. On days 6, 8, and 10 after the initial tumor inoculation, tumor-bearing mice were randomized for treatment, and wild-type VSV, AV3, or UVI was instilled into each mouse. Levels of tumor bioluminescence (a correlate of tumor size), and body weight (a key variable of animal health and indicator of treatment toxicity) were monitored for 22 days. Following three consecutive intravesical treatments of an oncolytic virus, there were no differences in weight between the treated mice (wild-type VSV and AV3) and the control mice (UV-inactivated wild-type VSV), regardless of tumor presence. In addition, tumor bioluminescence in the AV3 treated mice was slightly decreased (30%) compared to the control mice, but not different from the wild-type VSV treated mice. These data correspond to in vitro data which show that wild-type VSV and AV3 are inhibitors of proliferation in MBT-2 mouse bladder carcinoma cells. In conclusion, our data strongly suggest that oncolytic viruses such as wild-type VSV and its attenuated form, AV3, can be used to treat superficial bladder cancer in immune-competent mice, without adversely affecting the health and well-being of the animal. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2724. doi:10.1158/1538-7445.AM2011-2724
P162 A Two Month Prospective Study: Are Ctpas Requested Appropriately And If Not Do They Diagnose Alternative Pathologies?
Authors: S. Antoniou, H. Tung, S. Srivastava
Journal: Thorax (2014)

<h3>Introduction</h3> Pulmonary Embolisms (PE) are clinically difficult to diagnose and associated with significant morbidity and mortality. Computerised Tomography Pulmonary Angiogram (CTPA) is routinely used to investigate suspected PE. Clinical concern and the increased availability of CTPA may mean that more patients may be receiving unnecessary radiation: a CTPA is approximately 15 mSv, equivalent to 750 chest radiographs.<sup>1</sup> In addition, detection of other pathology by CTPA often has minimal clinical impact.<sup>2</sup> <h3>Aims</h3> To investigate our compliance with NICE guidelines in ordering CTPAs, and whether detecting alternative diagnoses justifies their use. <h3>Methods</h3> This prospective study, in a London teaching hospital, reviewed data in all medical and oncology patients who had a CTPA from January to February 2014. Clinical diagnoses and risk scores were recorded according to national guidelines. <h3>Results</h3> A CTPA was carried out on 91 patients (63% female); 20 had confirmed PE (22%). In 50 (55%), guidelines were not followed: 43 did not have D-dimers, of these 15 (35%) had cancer. Of those with PE, 35% were detected despite low Wells Scores (n = 7). In 47 (52%) alternative diagnoses made on CTPA accounted for the presenting symptoms: 18 diagnoses were newly made on CTPA but only 13 led to a change in management. Incidental findings requiring following were made in 9. <h3>Conclusions</h3> PEs remain difficult to diagnose. Clinical skills may not be accurate; our detection rate was 22%. In 55% NICE guidelines were not followed. In 15 this was due to d dimers not being performed in patients with cancer. The testing of d dimers is not routinely performed in our trust in patients with cancer, due to reduced clinical usefulness. A better scoring system may be required especially in cancer patients. Alternative diagnoses made on CTPA do not appear to alter management in the majority, suggesting that they should not be used to make other diagnoses. More research is required in diagnosing PE to minimise radiation and contrast risks, and ensure CTPAs are of maximum clinical benefit. <h3>References</h3> Davies <i>et al</i>, <i>BMJ</i> 2011;342:d947 van ES <i>et al</i>, <i>Chest</i> 2013;144(6):1893–9
Risk of Thyroid Cancer After Diagnostic Doses of Radioiodine
Authors: V. E. ARCHER
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Risk of Thyroid Cancer After Diagnostic Doses of Radioiodine Get access VICTOR E. ARCHER VICTOR E. ARCHER Rocky Mountain Center for Occupational and Environmental Health University of Utah Medical CenterBldg. 512 Salt Lake City, UT 84112 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 9, 3 May 1989, Pages 713–714, https://doi.org/10.1093/jnci/81.9.713 Published: 03 May 1989
A6.13 Identification of novel expression quantitative trait loci in CD4<sup>+</sup>T cells of untreated early arthritis patients
Authors: AG Pratt, J Massey, AE Anderson, N Nair, J Diboll, A Skelton, DW Lendrem, LN Reynard, HJ Cordell, S Eyre, A Barton, JD Isaacs
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is a CD4<sup>+</sup> T-cell-mediated disease of immune dysregulation. Genome-wide association scans (GWAS) have shown common variants at approximately 100 genetic loci to be associated with RA. In many cases, however, the associated single nucleotide polymorphisms (SNPs) lie in intergenic regions and the gene upon which they act has not yet been defined. Examining how RA-associated SNPs influence gene expression in relevant biological contexts will begin to address this. <h3>Methods</h3> Patients attending the Newcastle Early Arthritis Clinic, naïve to immunomodulatory therapy, donated high integrity RNA and DNA extracted from 98% pure CD4<sup>+</sup> T cells within 4 h of blood draw. Detailed baseline and longitudinal clinical data were recorded for all participants, who were followed up for ≥1 year. Genotyping and global gene expression measurement was carried out using the Illumina Human CoreExome array, and either HT12v4 or WG6v3 BeadChip arrays, respectively, and expression data was batch-corrected and normalised using standard algorithms. Data were analysed using the R package. Variants in linkage disequilibrium (LD) with 100 confirmed RA- SNPs (r<sup>2</sup> &gt;0.8), and probes within 4MB of these LD blocks, were included in the analysis, seeking evidence of cis-eQTLs. <h3>Results</h3> Data from 249 white Caucasian early arthritis patients were available for analysis; diagnoses (confirmed at follow-up) were RA (n = 88), spondyloarthropathy/other inflammatory arthritis (n = 86), osteoarthritis/other non-inflammatory arthralgia (n = 70) and undifferentiated arthritis. Analysis of 1,247 SNPs and 8,023 probes identified strong evidence for cis-eQTLs at a number of RA risk loci in this population overall (experiment-wide p &lt; 0.05). Previously observed genes subject to eQTLs in primary human CD4<sup>+</sup> T cells replicated by our study include <i>BLK</i>, <i>FADS1</i> and <i>FADS2</i>. Genes whose expression specifically in these cells has, to our knowledge, been associated with RA risk variants for the first time include <i>RPS26</i>, <i>RNF67 </i>and<i> IKZF3</i>. <h3>Conclusions</h3> We present the first detailed eQTL analysis in the pathophysiologically relevant setting of early arthritis CD4<sup>+</sup> T cells, free of confounding immunomodulatory treatment. Interactions of clinical parameters (including disease phenotype) with eQTL effects remains the subject of ongoing analyses, to be presented. Our findings have the potential to modify the biological candidate gene landscape of RA.